 |
 |

Genomic Profiles for Disease RiskPredictive or Premature?
Kenneth Offit, MD, MPH
JAMA. 2008;299(11):1353-1355.
 |
 |
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
 |
 |
There has been a recent explosion of commercial availability of genomic "tests" for diseases, conditions, traits, and ancestry. Dozens of companies advertise their services directly to consumers who, if they are willing to provide a DNA sample (usually from saliva) and are also willing to pay the charges, can obtain genetic information about various health conditions. These "conditions" range from the tendency to form wet vs dry earwax to risk for significant adult-onset diseases (Table).1
Table appears in full text version.
|
|
|
|
Table. Examples of Commercial Direct-to-Consumer Genomic and Genetic Testing Laboratoriesa
|
|
|
Unlike a decade ago, when DNA tests for cancer risk were carefully introduced to health care professionals in advance of widespread marketing,2 in 2008 the commercialization of genomic profiling started as a for-profit direct-to-consumer marketing campaign largely intended to bypass health care professionals. Now, most physicians learn through the media of the availability of "genome scans" that can be . . . [Full Text of this Article]
Author Affiliation: Clinical Genetics Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York.
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Neuroblastoma -- Linking a Common Allele to a Rare Disease
Kushner and Cheung
NEJM 2008;358:2635-2637.
FULL TEXT
Genetics and Genomics for Clinicians
Fontanarosa et al.
JAMA 2008;299:1364-1365.
FULL TEXT
|